JP2023524430A - Ｂｃｍａ指向性ｔ細胞療法と免疫調節化合物との併用 - Google Patents

Ｂｃｍａ指向性ｔ細胞療法と免疫調節化合物との併用 Download PDF

Info

Publication number
JP2023524430A
JP2023524430A JP2022565760A JP2022565760A JP2023524430A JP 2023524430 A JP2023524430 A JP 2023524430A JP 2022565760 A JP2022565760 A JP 2022565760A JP 2022565760 A JP2022565760 A JP 2022565760A JP 2023524430 A JP2023524430 A JP 2023524430A
Authority
JP
Japan
Prior art keywords
cells
days
administration
compound
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524430A5 (cg-RX-API-DMAC10.html
Inventor
マイケル ポーツ
オレクサンドル バトゥレビッチ
ネハ ソニ
ジョン－マイケル ウィリフォード
メリッサ ワークス
Original Assignee
ジュノー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュノー セラピューティクス インコーポレイテッド filed Critical ジュノー セラピューティクス インコーポレイテッド
Publication of JP2023524430A publication Critical patent/JP2023524430A/ja
Publication of JP2023524430A5 publication Critical patent/JP2023524430A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022565760A 2020-04-28 2021-04-27 Ｂｃｍａ指向性ｔ細胞療法と免疫調節化合物との併用 Pending JP2023524430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016983P 2020-04-28 2020-04-28
US63/016,983 2020-04-28
PCT/US2021/029503 WO2021222330A2 (en) 2020-04-28 2021-04-27 Combination of bcma-directed t cell therapy and an immunomodulatory compound

Publications (2)

Publication Number Publication Date
JP2023524430A true JP2023524430A (ja) 2023-06-12
JP2023524430A5 JP2023524430A5 (cg-RX-API-DMAC10.html) 2024-05-09

Family

ID=76502791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565760A Pending JP2023524430A (ja) 2020-04-28 2021-04-27 Ｂｃｍａ指向性ｔ細胞療法と免疫調節化合物との併用

Country Status (11)

Country Link
US (1) US20230165872A1 (cg-RX-API-DMAC10.html)
EP (1) EP4142723A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023524430A (cg-RX-API-DMAC10.html)
KR (1) KR20230015921A (cg-RX-API-DMAC10.html)
CN (1) CN116157125A (cg-RX-API-DMAC10.html)
AU (1) AU2021263765A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022021788A2 (cg-RX-API-DMAC10.html)
CA (1) CA3181399A1 (cg-RX-API-DMAC10.html)
IL (1) IL297688A (cg-RX-API-DMAC10.html)
MX (1) MX2022013530A (cg-RX-API-DMAC10.html)
WO (1) WO2021222330A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
CN118201618A (zh) * 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
EP4412713A1 (en) * 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
CA3205511A1 (en) * 2023-04-19 2025-03-17 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025137751A1 (pt) * 2023-12-26 2025-07-03 Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein Polinucleotídeo, receptor de antígeno quimérico, vetor, composição, método para produção de célula imune efetora modificada e uso do polinucleotídeo

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204427A1 (en) * 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
WO2019014100A1 (en) * 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
WO2019090003A1 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
JP2020502048A (ja) * 2016-11-04 2020-01-23 ブルーバード バイオ， インコーポレイテッド 抗ｂｃｍａ ｃａｒ ｔ細胞組成物
JP2022512971A (ja) * 2018-11-08 2022-02-07 ジュノー セラピューティクス インコーポレイテッド 処置およびｔ細胞調節のための方法および併用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7204296B2 (en) 2004-07-26 2007-04-17 Metal Casting Technology, Incorporated Method of removing a fugitive pattern from a mold
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
BR112017005766B1 (pt) 2014-09-22 2022-10-25 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
EP4549554A3 (en) 2017-07-29 2025-08-06 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
US12473345B2 (en) * 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN113747896A (zh) * 2019-04-22 2021-12-03 斯塔顿治疗公司 来那度胺和其他免疫调节剂的连续递送
EP4054623A1 (en) * 2019-11-07 2022-09-14 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502048A (ja) * 2016-11-04 2020-01-23 ブルーバード バイオ， インコーポレイテッド 抗ｂｃｍａ ｃａｒ ｔ細胞組成物
WO2018204427A1 (en) * 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
WO2019014100A1 (en) * 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
WO2019090003A1 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
JP2022512971A (ja) * 2018-11-08 2022-02-07 ジュノー セラピューティクス インコーポレイテッド 処置およびｔ細胞調節のための方法および併用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BJORKLUND C. C. ET AL., LEUKEMIA, vol. 34, JPN6025022306, 12 November 2019 (2019-11-12), pages 1197 - 1201, ISSN: 0005790863 *
BJORKLUND CHAD C. ET AL., LEUKEMIA, vol. 34, JPN6026004640, 2019, pages 1197 - 1201, ISSN: 0005790862 *
HANSEN J. D. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, JPN6025022307, 4 March 2020 (2020-03-04), pages 6648 - 6676, ISSN: 0005790860 *
J. MED. CHEM., vol. 61, JPN6026004641, 2018, pages 535 - 542, ISSN: 0005790861 *
WANG X. ET AL., CLIN CANCER RES, vol. 24(1), JPN6025022305, 2018, pages 106 - 119, ISSN: 0005790864 *

Also Published As

Publication number Publication date
WO2021222330A2 (en) 2021-11-04
IL297688A (en) 2022-12-01
KR20230015921A (ko) 2023-01-31
MX2022013530A (es) 2023-02-01
BR112022021788A2 (pt) 2023-01-17
CA3181399A1 (en) 2021-11-04
EP4142723A2 (en) 2023-03-08
CN116157125A (zh) 2023-05-23
WO2021222330A3 (en) 2021-12-09
US20230165872A1 (en) 2023-06-01
AU2021263765A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP7410877B2 (ja) キメラ抗原受容体（ｃａｒ）ｔ細胞療法とキナーゼ阻害剤の併用療法
JP2025087780A (ja) 処置およびｔ細胞調節のための方法および併用
JP7383620B2 (ja) 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
WO2017214207A2 (en) Methods for the treatment of b cell malignancies using adoptive cell therapy
US20230165872A1 (en) Combination of bcma-directed t cell therapy and an immunomodulatory compound
US20240197871A1 (en) Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
JP7837864B2 (ja) Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用
JP2024514163A (ja) Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
KR20240112994A (ko) 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
CN118450901A (zh) 用于治疗骨髓瘤的b细胞成熟抗原特异性嵌合抗原受体
EP4011381A1 (en) Adoptive cell therapies as early treatment options

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260514

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260707